Avenue Therapeutics (NASDAQ:ATXI) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Share on StockTwits

Avenue Therapeutics (NASDAQ:ATXI) released its quarterly earnings data on Wednesday. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.05, Bloomberg Earnings reports.

ATXI traded up $0.09 on Thursday, hitting $6.00. The company’s stock had a trading volume of 176 shares, compared to its average volume of 13,701. The stock’s 50 day simple moving average is $6.04. The stock has a market cap of $99.36 million, a price-to-earnings ratio of -2.86 and a beta of -0.41. Avenue Therapeutics has a 12 month low of $2.08 and a 12 month high of $7.98.

Several research analysts recently commented on the stock. ValuEngine raised shares of Avenue Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Avenue Therapeutics in a report on Tuesday, May 14th.

In other news, Director Neil Herskowitz purchased 5,000 shares of the business’s stock in a transaction on Tuesday, June 18th. The stock was purchased at an average cost of $5.86 per share, with a total value of $29,300.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Joseph Walter Vazzano sold 4,688 shares of the firm’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $5.59, for a total transaction of $26,205.92. Following the completion of the transaction, the chief financial officer now directly owns 59,038 shares of the company’s stock, valued at $330,022.42. The disclosure for this sale can be found here. 5.00% of the stock is currently owned by company insiders.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

See Also: Net Income

Earnings History for Avenue Therapeutics (NASDAQ:ATXI)

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.